Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus LR607 + neoadjuvant chemoimmunotherapy
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Lactobacillus rhamnosus LR607 + neoadjuvant chemoimmunotherapy is an investigational combination regimen being evaluated by Zhujiang Hospital for the treatment of resectable stage IIB-IIIB non-small cell lung cancer (NSCLC). The regimen consists of the oral probiotic strain LR607, which is selected for high expression of DL-peptidase, administered alongside standard-of-care neoadjuvant chemoimmunotherapy. The probiotic component is intended to modulate the gut microbiota and metabolic profiles, potentially enhancing the major pathological response (MPR) and overall efficacy of the chemoimmunotherapeutic agents. This approach leverages the gut-lung axis to improve clinical outcomes in lung cancer patients by optimizing the microbiome's influence on systemic immune responses.
- Other names
- Lactobacillus rhamnosus LR607Probiotics with high expression of DL-peptidase (LR607)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DL-peptidase (Gamma-D-glutamyl-meso-diaminopimelic acid peptidase)DNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on Lactobacillus rhamnosus LR607 + neoadjuvant chemoimmunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus LR607 + neoadjuvant chemoimmunotherapy.